Literature DB >> 33547148

Sotorasib Edges Closer to Approval.

.   

Abstract

The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID： 33547148     DOI： 10.1158/2159-8290.CD-NB2021-0309

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

Review 1.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

2.  Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients.

Authors:  Paola Ulivi; Milena Urbini; Elisabetta Petracci; Matteo Canale; Alessandra Dubini; Daniela Bartolini; Daniele Calistri; Paola Cravero; Eugenio Fonzi; Giovanni Martinelli; Ilaria Priano; Kalliopi Andrikou; Giuseppe Bronte; Lucio Crinò; Angelo Delmonte
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

3.  Comprehensive tumor molecular profile analysis in clinical practice.

Authors:  Mustafa Özdoğan; Eirini Papadopoulou; Nikolaos Tsoulos; Aikaterini Tsantikidi; Vasiliki-Metaxa Mariatou; Georgios Tsaousis; Evgenia Kapeni; Evgenia Bourkoula; Dimitrios Fotiou; Georgios Kapetsis; Ioannis Boukovinas; Nikolaos Touroutoglou; Athanasios Fassas; Achilleas Adamidis; Paraskevas Kosmidis; Dimitrios Trafalis; Eleni Galani; George Lypas; Bülent Orhan; Sualp Tansan; Tahsin Özatlı; Onder Kırca; Okan Çakır; George Nasioulas
Journal:  BMC Med Genomics       Date:  2021-04-14       Impact factor: 3.063

Review 4.  The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.

Authors:  Miriam Grazia Ferrara; Alessio Stefani; Sara Pilotto; Carmine Carbone; Emanuele Vita; Mariantonietta Di Salvatore; Ettore D'Argento; Ileana Sparagna; Federico Monaca; Giustina Valente; Antonio Vitale; Geny Piro; Lorenzo Belluomini; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

5.  Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides.

Authors:  Alexandra Maria Psaras; Simonas Valiuska; Véronique Noé; Carlos J Ciudad; Tracy A Brooks
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

6.  Indoloquinoline-Mediated Targeted Downregulation of KRAS through Selective Stabilization of the Mid-Promoter G-Quadruplex Structure.

Authors:  Alexandra Maria Psaras; Rhianna K Carty; Jared T Miller; L Nathan Tumey; Tracy A Brooks
Journal:  Genes (Basel)       Date:  2022-08-13       Impact factor: 4.141
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.